Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Antibody-Mediated Targeting of Tau In Vivo Does Not Require Effector Function and Microglial Engagement.

Lee SH, Le Pichon CE, Adolfsson O, Gafner V, Pihlgren M, Lin H, Solanoy H, Brendza R, Ngu H, Foreman O, Chan R, Ernst JA, DiCara D, Hotzel I, Srinivasan K, Hansen DV, Atwal J, Lu Y, Bumbaca D, Pfeifer A, Watts RJ, Muhs A, Scearce-Levie K, Ayalon G.

Cell Rep. 2016 Aug 9;16(6):1690-1700. doi: 10.1016/j.celrep.2016.06.099. Epub 2016 Jul 28.

2.

Prospective Design of Anti-Transferrin Receptor Bispecific Antibodies for Optimal Delivery into the Human Brain.

Kanodia JS, Gadkar K, Bumbaca D, Zhang Y, Tong RK, Luk W, Hoyte K, Lu Y, Wildsmith KR, Couch JA, Watts RJ, Dennis MS, Ernst JA, Scearce-Levie K, Atwal JK, Ramanujan S, Joseph S.

CPT Pharmacometrics Syst Pharmacol. 2016 May;5(5):283-91. doi: 10.1002/psp4.12081. Epub 2016 May 17.

3.

Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor.

Deng R, Bumbaca D, Pastuskovas CV, Boswell CA, West D, Cowan KJ, Chiu H, McBride J, Johnson C, Xin Y, Koeppen H, Leabman M, Iyer S.

MAbs. 2016;8(3):593-603. doi: 10.1080/19420862.2015.1136043. Epub 2016 Feb 26.

4.

Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies.

Zuchero YJ, Chen X, Bien-Ly N, Bumbaca D, Tong RK, Gao X, Zhang S, Hoyte K, Luk W, Huntley MA, Phu L, Tan C, Kallop D, Weimer RM, Lu Y, Kirkpatrick DS, Ernst JA, Chih B, Dennis MS, Watts RJ.

Neuron. 2016 Jan 6;89(1):70-82. doi: 10.1016/j.neuron.2015.11.024. Epub 2015 Dec 10.

5.

A novel in vitro method to model the fate of subcutaneously administered biopharmaceuticals and associated formulation components.

Kinnunen HM, Sharma V, Contreras-Rojas LR, Yu Y, Alleman C, Sreedhara A, Fischer S, Khawli L, Yohe ST, Bumbaca D, Patapoff TW, Daugherty AL, Mrsny RJ.

J Control Release. 2015 Sep 28;214:94-102. doi: 10.1016/j.jconrel.2015.07.016. Epub 2015 Jul 22.

PMID:
26210441
6.

Non-Clinical Disposition and Metabolism of DM1, a Component of Trastuzumab Emtansine (T-DM1), in Sprague Dawley Rats.

Shen BQ, Bumbaca D, Yue Q, Saad O, Tibbitts J, Khojasteh SC, Girish S.

Drug Metab Lett. 2015;9(2):119-31.

PMID:
26031461
7.

Dose dependent pharmacokinetics, tissue distribution, and anti-tumor efficacy of a humanized monoclonal antibody against DLL4 in mice.

Kamath AV, Yip V, Gupta P, Boswell CA, Bumbaca D, Haughney P, Castro J, Tsai SP, Pacheco G, Ross S, Yan M, Damico-Beyer LA, Khawli L, Shen BQ.

MAbs. 2014;6(6):1631-7. doi: 10.4161/mabs.36107.

8.

Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates.

Yu YJ, Atwal JK, Zhang Y, Tong RK, Wildsmith KR, Tan C, Bien-Ly N, Hersom M, Maloney JA, Meilandt WJ, Bumbaca D, Gadkar K, Hoyte K, Luk W, Lu Y, Ernst JA, Scearce-Levie K, Couch JA, Dennis MS, Watts RJ.

Sci Transl Med. 2014 Nov 5;6(261):261ra154. doi: 10.1126/scitranslmed.3009835.

9.

Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1).

Uppal H, Doudement E, Mahapatra K, Darbonne WC, Bumbaca D, Shen BQ, Du X, Saad O, Bowles K, Olsen S, Lewis Phillips GD, Hartley D, Sliwkowski MX, Girish S, Dambach D, Ramakrishnan V.

Clin Cancer Res. 2015 Jan 1;21(1):123-33. doi: 10.1158/1078-0432.CCR-14-2093. Epub 2014 Nov 4.

10.

Comparative physiology of mice and rats: radiometric measurement of vascular parameters in rodent tissues.

Boswell CA, Mundo EE, Ulufatu S, Bumbaca D, Cahaya HS, Majidy N, Van Hoy M, Schweiger MG, Fielder PJ, Prabhu S, Khawli LA.

Mol Pharm. 2014 May 5;11(5):1591-8. doi: 10.1021/mp400748t. Epub 2014 Apr 21.

PMID:
24702191
11.

Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptor.

Yip V, Palma E, Tesar DB, Mundo EE, Bumbaca D, Torres EK, Reyes NA, Shen BQ, Fielder PJ, Prabhu S, Khawli LA, Boswell CA.

MAbs. 2014 May-Jun;6(3):689-96. doi: 10.4161/mabs.28254. Epub 2014 Feb 26.

12.

Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants.

Bien-Ly N, Yu YJ, Bumbaca D, Elstrott J, Boswell CA, Zhang Y, Luk W, Lu Y, Dennis MS, Weimer RM, Chung I, Watts RJ.

J Exp Med. 2014 Feb 10;211(2):233-44. doi: 10.1084/jem.20131660. Epub 2014 Jan 27.

13.

Enhanced tumor retention of a radiohalogen label for site-specific modification of antibodies.

Boswell CA, Marik J, Elowson MJ, Reyes NA, Ulufatu S, Bumbaca D, Yip V, Mundo EE, Majidy N, Van Hoy M, Goriparthi SN, Trias A, Gill HS, Williams SP, Junutula JR, Fielder PJ, Khawli LA.

J Med Chem. 2013 Dec 12;56(23):9418-26. doi: 10.1021/jm401365h. Epub 2013 Nov 5.

PMID:
24131491
14.

A strategy for risk mitigation of antibodies with fast clearance.

Hötzel I, Theil FP, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, Fielder P, Carter PJ, Kelley RF.

MAbs. 2012 Nov-Dec;4(6):753-60. doi: 10.4161/mabs.22189.

15.

Vascular physiology and protein disposition in a preclinical model of neurodegeneration.

Boswell CA, Mundo EE, Johnstone B, Ulufatu S, Schweiger MG, Bumbaca D, Fielder PJ, Prabhu S, Khawli LA.

Mol Pharm. 2013 May 6;10(5):1514-21. doi: 10.1021/mp3004786. Epub 2013 Feb 25.

PMID:
23383983
16.

Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations.

Boswell CA, Bumbaca D, Fielder PJ, Khawli LA.

AAPS J. 2012 Sep;14(3):612-8. doi: 10.1208/s12248-012-9374-1. Epub 2012 May 31.

17.

Physiochemical and biochemical factors influencing the pharmacokinetics of antibody therapeutics.

Bumbaca D, Boswell CA, Fielder PJ, Khawli LA.

AAPS J. 2012 Sep;14(3):554-8. doi: 10.1208/s12248-012-9369-y. Epub 2012 May 18. Review.

18.

Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism.

Shen BQ, Bumbaca D, Saad O, Yue Q, Pastuskovas CV, Khojasteh SC, Tibbitts J, Kaur S, Wang B, Chu YW, LoRusso PM, Girish S.

Curr Drug Metab. 2012 Sep 1;13(7):901-10.

PMID:
22475269
19.

Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration.

Zheng Y, Tesar DB, Benincosa L, Birnböck H, Boswell CA, Bumbaca D, Cowan KJ, Danilenko DM, Daugherty AL, Fielder PJ, Grimm HP, Joshi A, Justies N, Kolaitis G, Lewin-Koh N, Li J, McVay S, O'Mahony J, Otteneder M, Pantze M, Putnam WS, Qiu ZJ, Ruppel J, Singer T, Stauch O, Theil FP, Visich J, Yang J, Ying Y, Khawli LA, Richter WF.

MAbs. 2012 Mar-Apr;4(2):243-55. doi: 10.4161/mabs.4.2.19387. Epub 2012 Mar 1.

20.

A case study on Sema3E-Fc aggregation and assay-dependent differences in quantitation.

Bumbaca D, Tong RK, Koch AW, Xiang H, DeForge LE, Shen BQ, Lu Y.

Bioanalysis. 2012 Mar;4(6):703-11. doi: 10.4155/bio.12.30.

PMID:
22452261
21.

Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model.

Pastuskovas CV, Mundo EE, Williams SP, Nayak TK, Ho J, Ulufatu S, Clark S, Ross S, Cheng E, Parsons-Reponte K, Cain G, Van Hoy M, Majidy N, Bheddah S, dela Cruz Chuh J, Kozak KR, Lewin-Koh N, Nauka P, Bumbaca D, Sliwkowski M, Tibbitts J, Theil FP, Fielder PJ, Khawli LA, Boswell CA.

Mol Cancer Ther. 2012 Mar;11(3):752-62. doi: 10.1158/1535-7163.MCT-11-0742-T. Epub 2012 Jan 5.

22.

Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice.

Bumbaca D, Xiang H, Boswell CA, Port RE, Stainton SL, Mundo EE, Ulufatu S, Bagri A, Theil FP, Fielder PJ, Khawli LA, Shen BQ.

Br J Pharmacol. 2012 May;166(1):368-77. doi: 10.1111/j.1476-5381.2011.01777.x.

23.

Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.

Boswell CA, Mundo EE, Zhang C, Bumbaca D, Valle NR, Kozak KR, Fourie A, Chuh J, Koppada N, Saad O, Gill H, Shen BQ, Rubinfeld B, Tibbitts J, Kaur S, Theil FP, Fielder PJ, Khawli LA, Lin K.

Bioconjug Chem. 2011 Oct 19;22(10):1994-2004. doi: 10.1021/bc200212a. Epub 2011 Oct 3.

PMID:
21913715
24.

Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4.

Bumbaca D, Wong A, Drake E, Reyes AE 2nd, Lin BC, Stephan JP, Desnoyers L, Shen BQ, Dennis MS.

MAbs. 2011 Jul-Aug;3(4):376-86. Epub 2011 Jul 1.

25.

Effects of anti-VEGF on predicted antibody biodistribution: roles of vascular volume, interstitial volume, and blood flow.

Boswell CA, Ferl GZ, Mundo EE, Bumbaca D, Schweiger MG, Theil FP, Fielder PJ, Khawli LA.

PLoS One. 2011 Mar 15;6(3):e17874. doi: 10.1371/journal.pone.0017874.

26.

Structure of a protein-DNA complex essential for DNA protection in spores of Bacillus species.

Lee KS, Bumbaca D, Kosman J, Setlow P, Jedrzejas MJ.

Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):2806-11. doi: 10.1073/pnas.0708244105. Epub 2008 Feb 19.

27.

Crystallization and preliminary X-ray analysis of the complex between a Bacillus subtilis alpha/beta-type small acid-soluble spore protein and DNA.

Bumbaca D, Kosman J, Setlow P, Henderson RK, Jedrzejas MJ.

Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Jun 1;63(Pt 6):503-6. Epub 2007 May 12.

28.

Genome-based identification and characterization of a putative mucin-binding protein from the surface of Streptococcus pneumoniae.

Bumbaca D, Littlejohn JE, Nayakanti H, Lucas AH, Rigden DJ, Galperin MY, Jedrzejas MJ.

Proteins. 2007 Feb 15;66(3):547-58.

PMID:
17115425
29.

Sequence analysis and characterization of a novel fibronectin-binding repeat domain from the surface of Streptococcus pneumoniae.

Bumbaca D, Littlejohn JE, Nayakanti H, Rigden DJ, Galperin MY, Jedrzejas MJ.

OMICS. 2004 Winter;8(4):341-56.

PMID:
15703481

Supplemental Content

Loading ...
Support Center